Albuterol Sulfate + Nicardipine Hydrochloride + Dobutamine Hydrochloride + Phenylephrine Hydrochloride + Verapamil Hydrochloride + Phentolamine Mesylate + Placebo
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Drug-Related Side Effects and Adverse Reactions
Conditions
Drug-Related Side Effects and Adverse Reactions, Cardiovascular System Disease
Trial Timeline
Apr 24, 2017 → Feb 29, 2020
NCT ID
NCT03098680About Albuterol Sulfate + Nicardipine Hydrochloride + Dobutamine Hydrochloride + Phenylephrine Hydrochloride + Verapamil Hydrochloride + Phentolamine Mesylate + Placebo
Albuterol Sulfate + Nicardipine Hydrochloride + Dobutamine Hydrochloride + Phenylephrine Hydrochloride + Verapamil Hydrochloride + Phentolamine Mesylate + Placebo is a phase 1 stage product being developed by AstraZeneca for Drug-Related Side Effects and Adverse Reactions. The current trial status is terminated. This product is registered under clinical trial identifier NCT03098680. Target conditions include Drug-Related Side Effects and Adverse Reactions, Cardiovascular System Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03098680 | Phase 1 | Terminated |